Home › Cancer (all types) › NCT07735442
BRIDGE-SIC Efficacy Trial
Better Real-time Information on Documentation of Goals of Care for Engagement in Serious Illness Communication (BRIDGE-SIC)
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * DFCI Patients, defined as patients who have a DFCI medical record number. * Admitted to an inpatient solid tumor medical oncology service at BWH (including beds that are considered to be DFCI beds within BWH) * Age ≥ 18 years * Mortality prediction ≥ 25% * Admitted on a Sunday after 4pm through Friday at 4pm. These time restrictions are necessary for the workflow of this pragmatic pilot trial, as the intervention requires a staff member to send intervention emails during the work week but within \<= approximately 18 hours of admission. Accordingly, we will not enroll patients during holiday time periods (e.g., for a Monday holiday, enrollment would start on Monday at 4pm instead of Sunday at 4pm) or on days where staff absences (e.g., illness) preclude enrollment. Exclusion Criteria: • Patients with elective inpatient admissions (typically for planned administration of chemotherapy or other treatments)
About the study
This is a pragmatic, prospective, randomized clinical trial to test the effectiveness of large language model (LLM)-generated serious illness conversation (SIC) summaries delivered to patients' inpatient and outpatient clinicians at the time of hospital admission on the primary outcome of days in the hospital in the next 90 days.
What is being tested
- LLM-generated SIC summary email to clinical teams (behavioral)
Sponsor: Dana-Farber Cancer Institute · Participants: 600 · Started: Aug 4, 2026
Contact the study team
- Alexi A Wright, MD, MPH · Phone: 6176322334
- Charlotta J Lindvall, MD, PhD · Phone: 6175823491
Official record on ClinicalTrials.gov — NCT07735442
Locations in the U.S.
| Massachusetts | Brigham and Women's Hospital, Boston Dana Farber Cancer Institute, Boston |
Conditions
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.